Bernard L Marini

Jul 6, 2023 | pubmed.ncbi.nlm.nih.gov | Marini BL |Perissinotti AJ |Bernard L Marini |Aaron Goodman

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

Jul 3, 2023 | thelancet.com | Bernard L Marini |Aaron Goodman

We read the Viewpoint by Nicholas J Short and Hagop Kantarjian with interest.Although we share enthusiasm for novel agents in the treatment of acute lymphoblastic leukaemia, we caution against abandoning randomised controlled trials (RCTs). Single-arm phase 2 studies establish the activity of novel approaches, but not their efficacy. Without confirmatory RCTs, we will continue to repeat the errors of the past.

Mar 22, 2023 | hoparx.org | Bernard L Marini

Pharmacist’s Application to PracticeRetifanlimab-dlwr (Zynyz) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Corresponding FDA Drug Update:Accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinomaWhat is the potential role for retifanlimab-dlwr in the treatment of metastatic or recurrent locally advanced MCC?